epilepsydrug-resistant epilepsy in childrenantiepileptic drugperampanelэпилепсияфармакорезистентная эпилепсия у детейантиэпилептический препаратперампанел1.1. Айвазян С.О., Ширяев Ю.С. Современные методы лечения пациентов с фармакорезистентной эпилепсией, доступные в Российской Федерации. Эпилепсия и пароксизмальные состояния 2016;8(1):22–8. [Ayvazyan S.O., Shiryaev Yu.S. Treatment of drug-resistant epilepsy: methods, currently available in Russia. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxyzmal Conditions 2016;8(1):22–8. (In Russ.)].Айвазян С.О., Ширяев Ю.С. Современные методы лечения пациентов с фармакорезистентной эпилепсией, доступные в Российской Федерации. Эпилепсия и пароксизмальные состояния 2016;8(1):22–8. [Ayvazyan S.O., Shiryaev Yu.S. Treatment of drug-resistant epilepsy: methods, currently available in Russia. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxyzmal Conditions 2016;8(1):22–8. (In Russ.)].2.2. Белоусова Е.Д. Генетика эпилепсии: зачем и как обследовать детей с эпилепсией. Неврология, нейропсихиатрия, психосоматика 2014;6(suppl 1):4–8. [Belousova E.D. Genetics of epilepsy: why should we examine children with epilepsy and how to do it. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics 2014;6(suppl 1):4–8. (In Russ.)].Белоусова Е.Д. Генетика эпилепсии: зачем и как обследовать детей с эпилепсией. Неврология, нейропсихиатрия, психосоматика 2014;6(suppl 1):4–8. [Belousova E.D. Genetics of epilepsy: why should we examine children with epilepsy and how to do it. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics 2014;6(suppl 1):4–8. (In Russ.)].3.3. Жидкова И.А. Управление нежелательными явлениями, возникающими на фоне приема перампанела. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):13–4. [Zhidkova I.A. Management of adverse events in patients receiving perampanel. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxyzmal Conditions 2014; (special issue):13–4. (In Russ.)].Жидкова И.А. Управление нежелательными явлениями, возникающими на фоне приема перампанела. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):13–4. [Zhidkova I.A. Management of adverse events in patients receiving perampanel. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxyzmal Conditions 2014; (special issue):13–4. (In Russ.)].4.4. Карлов В.А. Фармакорезистентность и толерантность. В кн.: Эпилепсия у детей и взрослых женщин и мужчин: руководство для врачей. М.: Медицина, 2010. C. 667–676. [Karlov V.A. Drug resistance and tolerance. In: Epilepsy in children and adult women and men: a guideline for physicians. Moscow: Meditsina, 2010. Pp. 667–676. (In Russ.)].Карлов В.А. Фармакорезистентность и толерантность. В кн.: Эпилепсия у детей и взрослых женщин и мужчин: руководство для врачей. М.: Медицина, 2010. C. 667–676. [Karlov V.A. Drug resistance and tolerance. In: Epilepsy in children and adult women and men: a guideline for physicians. Moscow: Meditsina, 2010. Pp. 667–676. (In Russ.)].5.5. Карлов В.А., Беляев О.В., Власов П.Н. и др. Российский опыт применения перампанела в повседневной клинической практике. Неврология, нейропсихиатрия, психосоматика 2016;(suppl 1): 11–7. [Karlov V.A., Belyaev O.V., Vlasov P.N. et al. Russian experience of peram panel use in routine clinical practice. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics 2016;(suppl 1):11–7. (In Russ.)].Карлов В.А., Беляев О.В., Власов П.Н. и др. Российский опыт применения перампанела в повседневной клинической практике. Неврология, нейропсихиатрия, психосоматика 2016;(suppl 1): 11–7. [Karlov V.A., Belyaev O.V., Vlasov P.N. et al. Russian experience of peram panel use in routine clinical practice. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics 2016;(suppl 1):11–7. (In Russ.)].6.6. Мухин К.Ю., Миронов М.Б., Петру- хин А.С. Эпилептические синдромы. Диагностика и лечение. М.: Системные решения, 2014. 376 с. [Mukhin K.Yu., Mironov M.B., Petrukhin A.S. Epileptic syndromes. Diagnosis and treatment. Moscow: Sistemnye resheniya, 2014. 376 p. (In Russ.)].Мухин К.Ю., Миронов М.Б., Петру- хин А.С. Эпилептические синдромы. Диагностика и лечение. М.: Системные решения, 2014. 376 с. [Mukhin K.Yu., Mironov M.B., Petrukhin A.S. Epileptic syndromes. Diagnosis and treatment. Moscow: Sistemnye resheniya, 2014. 376 p. (In Russ.)].7.7. Мухин К.Ю., Пылаева О.А. Применение перампанела в лечении эпилепсии: обзор литературы и описание клиничес кого случая. Русский журнал детской неврологии 2016;11(2):52–62. [Mukhin K.Yu., Pylaeva O.A. Use of perampanel in the treatment of epilepsy: a review of literature and a case report. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2016;11(2):52–62. (In Russ.)].Мухин К.Ю., Пылаева О.А. Применение перампанела в лечении эпилепсии: обзор литературы и описание клиничес кого случая. Русский журнал детской неврологии 2016;11(2):52–62. [Mukhin K.Yu., Pylaeva O.A. Use of perampanel in the treatment of epilepsy: a review of literature and a case report. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2016;11(2):52–62. (In Russ.)].8.8. Aso K., Watanabe K. Limitations in the medical treatment of cryptogenic or symptomatic localization-related epilepsies of childhood onset. Epilepsia 2000;41 (suppl 9):18–20. PMID: 11156503.Aso K., Watanabe K. Limitations in the medical treatment of cryptogenic or symptomatic localization-related epilepsies of childhood onset. Epilepsia 2000;41 (suppl 9):18–20. PMID: 11156503.9.9. Berg A.T. Defining intractable epilepsy. Adv Neurol 2006;97:5–10. PMID: 16383109.Berg A.T. Defining intractable epilepsy. Adv Neurol 2006;97:5–10. PMID: 16383109.10.10. Berg A.T., Shinnar S., Levy S.R. et al. Early development of intractable epilepsy in children: a prospective study. Neurology 2001;56(11):1445–52. PMID: 11402099.Berg A.T., Shinnar S., Levy S.R. et al. Early development of intractable epilepsy in children: a prospective study. Neurology 2001;56(11):1445–52. PMID: 11402099.11.11. Besag F.M., Patsalos P.N. Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures. Neuropsychiatr Dis Treat 2016;12:1215– 20. DOI: 10.2147/NDT.S83842.Besag F.M., Patsalos P.N. Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures. Neuropsychiatr Dis Treat 2016;12:1215– 20. DOI: 10.2147/NDT.S83842.12.12. Biró A., Stephani U., Tarallo T. et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics 2015;46(2):110–6. DOI: 10.1055/s-0035-1546276.Biró A., Stephani U., Tarallo T. et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics 2015;46(2):110–6. DOI: 10.1055/s-0035-1546276.13.13. De Liso P., Vigevano F., Specchio N. et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies – an Italian observational multicenter study. Epilepsy Res 2016;127:93–100. DOI: 10.1016/j.eplepsyres.2016.08.021.De Liso P., Vigevano F., Specchio N. et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies – an Italian observational multicenter study. Epilepsy Res 2016;127:93–100. DOI: 10.1016/j.eplepsyres.2016.08.021.14.14. Kwan P., Arzimanoglou A., Berg A.T. et al. Definition of drug resistant epilepsy: consensus proposal by the Ad Hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2009;51(6):1069–77. DOI: 10.1111/j.1528-1167.2009.02397.x.Kwan P., Arzimanoglou A., Berg A.T. et al. Definition of drug resistant epilepsy: consensus proposal by the Ad Hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2009;51(6):1069–77. DOI: 10.1111/j.1528-1167.2009.02397.x.15.15. Kwong K.L., Sung W.Y., Wong S.N., So K.T. Early predictors of medical intractability in childhood epilepsy. Pediatric Neurol 2003;29(1):46–52. PMID: 13679121.Kwong K.L., Sung W.Y., Wong S.N., So K.T. Early predictors of medical intractability in childhood epilepsy. Pediatric Neurol 2003;29(1):46–52. PMID: 13679121.16.16. Paolicchi J.M. The spectrum of non-epileptic events in children. Epilepsia 2002;43(suppl 3):60–4. PMID: 12060007.Paolicchi J.M. The spectrum of non-epileptic events in children. Epilepsia 2002;43(suppl 3):60–4. PMID: 12060007.17.17. Rohracher A., Brigo F., Höfler J. et al. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy. Expert Opin Pharmacother 2016;17(10):1403–11. DOI: 10.1080/14656566.2016.1195810.Rohracher A., Brigo F., Höfler J. et al. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy. Expert Opin Pharmacother 2016;17(10):1403–11. DOI: 10.1080/14656566.2016.1195810.18.18. Sherman E.M.S., Connolly M.B., Slick D.J. et al. Quality of life and seizure outcome after vagus nerve stimulation in children with intractable epilepsy. J Child Neurol 2008;23(9):991–8. DOI: 10.1177/0883073808315417.Sherman E.M.S., Connolly M.B., Slick D.J. et al. Quality of life and seizure outcome after vagus nerve stimulation in children with intractable epilepsy. J Child Neurol 2008;23(9):991–8. DOI: 10.1177/0883073808315417.19.19. Singh K., Shah Y.D., Luciano D. et al. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: a single-center postmarketing study. Epilepsy Behav 2016;61(11):41–5. DOI: 10.1016/j.yebeh.2016.05.007.Singh K., Shah Y.D., Luciano D. et al. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: a single-center postmarketing study. Epilepsy Behav 2016;61(11):41–5. DOI: 10.1016/j.yebeh.2016.05.007.